What Changed

NurExone Biologic Inc. has an investor-relations agreement with RedChip Companies, Inc..

The RedChip agreement carries a fee of 65000.

NurExone Biologic Inc. is also participating in four major life sciences events.

Highlights

  • ExoPTEN is NurExone Biologic Inc.'s lead therapeutic candidate.
  • NurExone Biologic Inc. has a memorandum of understanding with Made Scientific.
  • The company has a two-week national television campaign.

Pipeline and Collaboration

NurExone Biologic Inc. identifies ExoPTEN as its lead therapeutic candidate.

The preclinical data for ExoPTEN concern acute spinal cord and optic nerve damage.

The company has a memorandum of understanding with Made Scientific.

Leadership and Publicity

Dr. Lior Shaltiel is CEO of NurExone Biologic Inc..

Dr. Tali Kizhner is R&D Director of NurExone Biologic Inc..

NurExone Biologic Inc.'s advertisement campaign is a two-week national television campaign.